UBIGENE

Application

application-banner
Application
  • All (302)
  • Case Study (64)
  • Expert Insights - Cell Culture (25)
  • Expert Insights - Cell Application (51)
  • Expert Insights - CRISPR Library (59)
  • Gene Editing Practical Tips (38)
  • Others (65)

IF=23.2 | Ubigene Luc Cells Support Research on Oat β-Glucan in Colorectal Cancer

Discover how oat β-glucan enhances anti-PD-1 efficacy in colorectal cancer by enriching F. prausnitzii and key metabolites like butyrate and IPA in this latest study.

type image

HepG2 Gene-Edited Cell Lines: Applications in Metabolic and Genetic Disease Research

Discover how HepG2 cell lines advance liver research, metabolic disease modeling, and drug screening, with insights on CRISPR/Cas9 editing and LDLR/ATP7B targets.

type image

Dual-action GPNMB CAR-T therapy clears glioblastoma and reshapes the myeloid-suppressive microenvironment

This study identifies GPNMB as a dual-target antigen in GBM, showing GPNMB CAR-T cells eliminate tumor cells and TAMs to overcome therapy resistance.

type image

A Comprehensive Guide to ID8-Luc Cells: A powerful Tool for Ovarian Cancer Research

Discover how ID8-Luc cell lines advance ovarian cancer research with real-time BLI imaging for in vivo immunotherapy, TME, and drug efficacy studies.

type image

Targeting CARM1 Relieves cDC1 Functional Suppression and Reshapes Antitumor Immunity via CrossPresentation

Discover how targeting the CARM1 epigenetic enzyme relieves cDC1 functional suppression, restores antigen cross-presentation, and enhances anti-tumor immunity.

type image
icon
to-top
Logo
E-mail: info@ubigene.com
WhatsAPP: +86 153 6067 3248
TEL: +86 153 6067 3248(Int'l)
Chat with an Expert
Logo
Logo
Logo
Logo
Logo
Logo
Logo
Copyright © 2025 Ubigene. All rights reserved.
Privacy PolicyImpressum